Myriocin

SKU: orb1220168

Description

Myriocin, a fungal metabolite isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin strongly suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection.

Key Properties

• CAS Number: 35891-70-4
• MW: 401.54
• Purity: >98% (HPLC)
• Formula: C??H??NO?
• SMILES: CCCCCCC(CCCCCC/C=C/C[C@@H](O)[C@H](O)[C@](CO)(N)C(O)=O)=O
• Target: HCV
• Solubility: DMSO : 5 mg/mL (12.45 mM; ultrasonic and warming and heat to 60°C)

Bioactivity

• In Vivo:
  Myriocin (Thermozymocidin; 0-1 mg/kg; i.p.; daily, for 5 d; male Balb/c mice) blocks de novo synthesis of sphingolipids In vivo by SPT inhibition and induced c-myc expression in liver. Animal model: Male Balb/c mice (22 g, 7-8 weeks old). Dosage: 0, 0.1, 0.3, and 1.0 mg/kg. Administration: Intraperitoneal injection; daily, for 5 days. Result: Altered not significantly the levels of plasma alanine aminotransferase and aspartate aminotransferase. Decreased free sphinganine in a dose-dependent manner in both the liver and kidney. Decreased in the activity of liver SPT with a correlation coefficient of-0.76.
• In Vitro:
  Myriocin (Thermozymocidin; 0-10000 nM; 96 h; Huh7/Rep-Feo cells) inhibits the replication of a subgenomic hepatitis C virus (HCV) genotype 1b replicon. Myriocin (100 nM; 72 h) decreases in the sphingomyelin content of Huh7 cells. Western blot analysis. Cell line: Huh7/Rep-Feo cells. Concentration: 0, 300, and 1000 nM. Incubation time: 96 hours. Result: Decreased the levels of HCV NS5A in a concentration-dependent manner.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

HCV